Soligenix

Ticker: SNGX

Sector: Biotechnology

Soligenix

Soligenix shares rise on receiving fda ind clearance for phase 2 clinical trial of dusquetide. The companys SGX945 Phase 2 pilot trial in aphthous ulcers of Behçets disease. Nano-cap biotech Soligenix ( NASDAQ: SNGX) gained over 200% on Thursday after announcing that the U.S. government has approved HyBryte™ for the treatment of cutaneous T-cell lymphoma. Soligenix has a variety of products in its pipeline, including its heat-stable ricin toxin vaccine, RiVax®. The cost of development and manufacturing for its flagship products is estimated to be in the range of $10 million to $20 million. Soligenix, Inc. performed a 1 for 15 Reverse Split. The company is a biopharmaceutical company that is publicly traded on the NASDAQ stock exchange under the ticker symbol SNGX The company focuses on developing treatments for rare diseases with unmet medical needs. FDA has cleared Soligenix Incs (SNGX) Investigational New Drug (IND) application for a Phase 2a clinical trial for SGX945 (dusquetide) for aphthous ulcers in Behçets disease. Soligenix: Witnessed a record-breaking daily growth of 332% of the 65-Day Volume Moving Average on August 15, 2023. Emerged as a top weekly gainer for penny stocks with a remarkable +16.01% rise. Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçets Disease. Company is focused on developing and commercializing products to treat rare diseases where there is an unmet need.